HC Wainwright Has Negative Outlook for ARTV Q3 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at HC Wainwright cut their Q3 2026 EPS estimates for Artiva Biotherapeutics in a research report issued on Friday, August 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.54) per share for the quarter, down from their prior estimate of ($0.50). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($2.45) per share. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($3.31) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($2.17) EPS and FY2030 earnings at $0.22 EPS.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Tuesday, July 21st. Wedbush lifted their price target on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a report on Tuesday, May 26th. Wall Street Zen raised Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.

Artiva Biotherapeutics Stock Down 0.4%

Shares of NASDAQ:ARTV opened at $11.22 on Tuesday. The firm has a market cap of $277.36 million, a price-to-earnings ratio of -3.40 and a beta of 2.16. Artiva Biotherapeutics has a 12 month low of $2.22 and a 12 month high of $14.53. The company’s fifty day simple moving average is $9.43 and its 200 day simple moving average is $7.81.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63).

Insider Activity

In related news, Director Ra Capital Management, L.P. acquired 24,944 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was bought at an average price of $9.93 per share, with a total value of $247,693.92. Following the acquisition, the director owned 17,329,570 shares in the company, valued at $172,082,630.10. This represents a 0.14% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 1,965,251 shares of company stock worth $16,188,035 and sold 53,040 shares worth $477,890. 1.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARTV. State of Wyoming acquired a new stake in Artiva Biotherapeutics in the second quarter valued at $45,000. Prelude Capital Management LLC bought a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at about $41,000. Bank of America Corp DE increased its stake in shares of Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after purchasing an additional 11,190 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Artiva Biotherapeutics during the 1st quarter worth about $131,000. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Artiva Biotherapeutics in the 4th quarter valued at about $91,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.